PDF icon Download PDF
Fortschr Neurol Psychiatr 2003; 71(10): 535-540
DOI: 10.1055/s-2003-42871
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Hyperlipidämie - Nebenwirkung von „atypischen” Neuroleptika?

Hyperlipidemia - Side-Effect of “Atypical” Neuroleptics?T.  Wetterling1
  • 1Klinik für Psychiatrie und Psychotherapie - Gerontopsychiatrie, Vivantes Klinikum Hellersdorf, Berlin
Further Information

Publication History

Publication Date:
10 October 2003 (online)

Also available ateRef
   Permissions and Reprints
Preview

Zusammenfassung

Nach der Markteinführung der so genannten ‚atypischen Neuroleptika’ sind eine Reihe von Berichten über erhöhte Blutfettwerte bei Patienten, die mit diesen Medikamenten behandelt wurden, veröffentlicht worden. In dieser Übersicht sollen die bisher in der Literatur beschriebenen Berichte und Studien referiert werden. Nach den bisher vorliegenden Daten ist eine Hyperlipidämie besonders bei Patienten, die mit Clozapin, Olanzapin und auch Quetiapin behandelt wurden, beobachtet worden. Es sind insbesondere starke Anstiege der Serumkonzentrationen der Triglyzeride berichtet worden. Die zugrunde liegenden Pathomechanismen sind noch nicht hinreichend geklärt. Da eine Hyperlipidämie ein wichtiger Aspekt des so genannten metabolischen Syndroms ist, das sehr häufig zu schwer wiegenden Folgeerkrankungen, v. a. Herz-/Kreislauferkrankungen, führt, sollte einer Hyperlipidämie als einer möglichen Nebenwirkung von Neuroleptika vermehrt Aufmerksamkeit gewidmet werden.

Abstract

After the introduction of the so-called ‘atypical antipsychotics’ some reports concerning hyperlipidemia observed in patients treated with these drugs have been published. The studies and case reports available up to now were reviewed. The available data show that hyperlipidemia particularly occurred in patients receiving clozapine, olanzapine and also quetiapine. Predominately elevated serum levels of triglycerides have been reported. The underlying pathomechanism still remains widely unclear. Since hyperlipidemia is an important symptom of the so called ‘metabolic syndrome’ which is often associated with severe complications like cardial and vascular diseases, more attention should be paid to hyperlipidemia as a potential side effect of antipsychotics.

Literatur

  • 1 Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2. Aufl. Bremen: Uni-Med 2000
    Search in Google Scholar
  • 2 Henderson D C. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities.  J Clin Psychiatry. 2001;  62 Suppl 23 39-44
    PubMedSearch in Google Scholar
  • 3 Kato M M, Goodnick P J. Antipsychotic medication: Effects on regulation of glucose and lipids.  Expert Opin Pharmacother. 2001;  2 1571-1582
    CrossrefPubMedSearch in Google Scholar
  • 4 Mclntyre R S, McCann S M, Kennedy S H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.  Can J Psychiatry. 2001;  46 273-281
    PubMedSearch in Google Scholar
  • 5 Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study.  Eur J Epidemiol. 1992;  8 Suppl 1 99-103
    CrossrefPubMedSearch in Google Scholar
  • 6 Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor.  Am J Cardiol. 2000;  86 943-949
    CrossrefPubMedSearch in Google Scholar
  • 7 Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor.  Clin Cardiol. 1999;  22 (6 Suppl) II1-6
    PubMedSearch in Google Scholar
  • 8 Laaser U. Nutzen und Kosten bei Früherkennung und Frühbehandlung der Hypercholesterinämie.  Z Kardiol. 1994;  83 Suppl 6 163-167
    PubMedSearch in Google Scholar
  • 9 Richter W O, Richter V, Rassoul F, Sonnichsen A C, Rotzsch W, Schwandt P. Kardiovaskuläre Risikofaktoren in den alten und neuen Bundesländern.  Fortschr Med. 1993;  111 214-218
    PubMedSearch in Google Scholar
  • 10 Spelsberg A, Weiland K, Stolpe S, Segerling M, Keil U. Bochumer Cholesterin und Blutdruckscreening-Studie 1990.  Fortschr Med. 1992;  110 387-392
    PubMedSearch in Google Scholar
  • 11 Hershcopf R J, Elahi D, Andres R, Baldwin H L, Raizes G S, Schocken D D, Tobin J D. Longitudinal changes in serum cholesterol in man: an epidemiologic search for an etiology.  J Chronic Dis. 1982;  35 101-114
    CrossrefPubMedSearch in Google Scholar
  • 12 McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma Insulin and triglyceride concentrations.  J Clin Endocrinol Metab. 2000;  85 3085-3088
    CrossrefPubMedSearch in Google Scholar
  • 13 Richter W O, Sonnichsen A C, Schwandt P. Results and efficacy of public screening for hypercholesterolemia: the Bavarian Cholesterol Screening Project.  J Clin Epidemiol. 1995;  48 1307-1317
    CrossrefPubMedSearch in Google Scholar
  • 14 Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.  JAMA. 2002;  287 356-359
    CrossrefPubMedSearch in Google Scholar
  • 15 Wetterling T. Hyperlipidämie - Nebenwirkung bei Behandlung mit einem atypischen Neuroleptikum (Zotepin)?.  Psychiat Prax. 2002;  29 438-440
    PubMedSearch in Google Scholar
  • 16 Koro C E, Fedder D O, Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.  Arch Gen Psychiatry. 2002;  59 1021-1026
    PubMedSearch in Google Scholar
  • 17 Clark M L, Johnson P C. Amenorrhea and elevated serum cholesterol produced by tri-fluoro-methylated phenothiazine.  J Clin Endocrinol Metab. 1960;  20 641-646
    PubMedSearch in Google Scholar
  • 18 Clark M L, Ray T S, Paredes A, Ragland R E, Costiloe J P, Smith C W, Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships.  Psychosom Med. 1967;  29 634-642
    PubMedSearch in Google Scholar
  • 19 Mefferd R B, Labrosse E H, Gawienowski A M. Influence of Chlorpromazine on biochemical variables of male schizophrenics.  J Nerv Ment Dis. 1958;  127 167-179
    PubMedSearch in Google Scholar
  • 20 Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquillizers.  Clin Pharmacol Ther. 1985;  37 684-687
    PubMedSearch in Google Scholar
  • 21 Lund B C, Perry P J, Brooks J M, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.  Arch Gen Psychiatry. 2001;  58 1172-1176
    PubMedSearch in Google Scholar
  • 22 Ghaeli P, Dufresne R L. Serum triglyceride levels in patients treated with clozapine.  Am J Health Sys Pharm. 1996;  53 2079-2081
    PubMedSearch in Google Scholar
  • 23 Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, Guy N, Gonen N, Weizman A. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.  Clin Neuropharmacol. 1998;  21 245-250
    PubMedSearch in Google Scholar
  • 24 Gaulin B D, Markowitz J S, Caley C F, Nesbitt L A, Dufresne R L. Clozapine-associated elevation in triglycerides.  Am J Psychiatry. 1999;  156 1270-1272
    PubMedSearch in Google Scholar
  • 25 Wirshing D A. Adverse effects of atypical antipsychotics.  J Clin Psychiatry. 2001;  62 Suppl 21 7-10
    PubMedSearch in Google Scholar
  • 26 Braun G A, Paulois M E. Sterol metabolism: biochemical differences among butyrophenons.  Int J Neuropsychiatry. 1967;  3 Suppl 26-27
    PubMedSearch in Google Scholar
  • 27 Clark M L, Braun G A, Hewson J R, Serafetinides E A, Colmore J P, Rahhai D K. Trifluoperidol and cholesterol in man.  Clin Pharmacol Ther. 1968;  9 333-340
    PubMedSearch in Google Scholar
  • 28 Serafetinides E A, Colmore J P, Rahhai D K, Clark M L. Trifluoperidol in chronic male psychiatric patients.  Behav Neuropsychiaty. 1971;  3 10-12
    PubMedSearch in Google Scholar
  • 29 Simpson G M, Cooper T B. The effect of three butyrophenones on serum cholesterol levels.  Curr Ther Res Clin Exp. 1966;  8 249-255
    PubMedSearch in Google Scholar
  • 30 Simpson G M, Cooper T B, Braun G A. Further studies on the effect of butyrophenons on cholesterol synthesis in humans.  Curr Ther Res Clin Exp. 1967;  9 413-418
    PubMedSearch in Google Scholar
  • 31 Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients.  Clin Pharmacol Ther. 1970;  11 883-889
    PubMedSearch in Google Scholar
  • 32 Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenics treated with phenothiazines.  Atherosclerosis. 1984;  51 163-169
    PubMedSearch in Google Scholar
  • 33 Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg l, Kotler M, Weizman A. The impact on serum lipids of clozapine treatment in chronic schizophrenic patients.  Clin Neuropharmacol. 1999;  2 98-101
    PubMedSearch in Google Scholar
  • 34 Meyer J M. A rectrospective comparison of weight, lipid, and glucose changes between olanzapine- and risperidone-treated inpatients: metabolic outcomes after 1 year.  J Clin Psychiatry. 2002;  63 425-433
    PubMedSearch in Google Scholar
  • 35 Simpson G, Romano S J, Horne R L. et al .Ziprasidone versus olanzapine in schizophrenia: Result of a double-blind study. New Orleans: American Psychiatric Association Annual Meeting, NR 252 2001: 68-69 (zitiert nach 3)
    Search in Google Scholar
  • 36 Dursun S M, Szemis A, Andrews H, Reveley M A. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.  J Psychiatry Neurosci. 1999;  24 453-455
    PubMedSearch in Google Scholar
  • 37 Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.  Am J Psychiatry. 2000;  157 975-981
    CrossrefPubMedSearch in Google Scholar
  • 38 Leonard P, Halley A, Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine.  Ir Med J. 2002;  95 119-120
    PubMedSearch in Google Scholar
  • 39 Meyer J M. Novel antipsychotics and severe hyperlipidemia.  J Clin Psychopharmacol. 2001;  21 369-374
    CrossrefPubMedSearch in Google Scholar
  • 40 Melkersson K l, Hulting A L, Brismar K E. Elevated levels of Insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.  J Clin Psychiatry. 2000;  61 742-749
    PubMedSearch in Google Scholar
  • 41 Osser D N, Najarian D M, Dufresne R L. Olanzapine increases weight and serum triglyceride levels.  J Clin Psychiatry. 1999;  60 767-770
    PubMedSearch in Google Scholar
  • 42 Sheitman B B, Bird P M, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels.  Am J Psychiatry. 1999;  156 1471-1472
    PubMedSearch in Google Scholar
  • 43 Kinon B J, Basson B R, Gilmore J A, Tollefson G D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.  J Clin Psychiatry. 2001;  62 92-100
    PubMedSearch in Google Scholar
  • 44 Daniel D G, Zimbroff D L, Potkin S G, Reeves K R, Harrigan E P, Lakshminarayanan M I. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.  Neuropsychopharmacology. 1999;  20 491-505
    CrossrefPubMedSearch in Google Scholar
  • 45 Keck Jr P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan E P, Morrissey M R. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.  Psychopharmacology. 1998;  140 173-184
    CrossrefPubMedSearch in Google Scholar
  • 46 Kingsbury S J, Fayek M, Trufasiu D, Zada J, Simpson G M. The effects of Ziprasidone on cholesterol, triglycerides and glucose.  J Clin Psychiatry. 2001;  62 347-349
    PubMedSearch in Google Scholar
  • 47 Romano S J, Cutler N, Weiden P J, Simpson G M. Ziprasidone's effects on weight and lipids in patients with schizophrenia. Montreal: Poster, 23th Congress 23. - 27. 6. 2002
  • 48 Wetterling T. Gewichtszunahme - eine unterschätzte Nebenwirkung atypischer Neuroleptika?.  Fortschr Neurol Psychiat. 2000;  68 546-556
    PubMedSearch in Google Scholar
  • 49 Brown C D, Higgins M, Donato K A, Rohde F C, Garrison R, Obarzanek E, Ernst N D, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia.  Obes Res. 2000;  8 605-619
    CrossrefPubMedSearch in Google Scholar
  • 50 Denke M A, Sempos C T, Grundy S M. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men.  Arch Intern Med. 1993;  153 1093-1103
    CrossrefPubMedSearch in Google Scholar
  • 51 Denke M A, Sempos C T, Grundy S M. Excess body weight. An underrecognized contributor to dyslipidemia in white American women.  Arch Intern Med. 1994;  154 401-410
    CrossrefPubMedSearch in Google Scholar
  • 52 Thune l, Njolstad l, Lochen M L, Forde O H. Physical activity improves the metabolic risk profiles in men and women: the Tromsö Study.  Arch Intern Med. 1998;  158 1633-1640
    CrossrefPubMedSearch in Google Scholar
  • 53 Ferreira M F, Sobrinho L G, Santos M A, Sousa M F, Uvnas-Moberg K. Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone.  Psychoneuroendocrinol. 1998;  23 1005-1013
    PubMedSearch in Google Scholar
  • 54 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.  Clin Endocrinol. 1998;  48 547-553
    CrossrefPubMedSearch in Google Scholar
  • 55 Bapista T, Lacruz A, Mendoza S de, Mendoza Guilleri J M, Silvera A, Angeles F, Mendoza M T, Hernandez L. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones.  Pharmacopsychiatry. 2000;  33 81-88
    Thieme ConnectPubMedSearch in Google Scholar
  • 56 Brömel T, Blum W F, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg J-C, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy.  Mol Psychiatry. 1998;  3 76-80
    CrossrefPubMedSearch in Google Scholar
  • 57 Kraus T, Zimmermann U, Schuld A, Haack M, Hinze-Selch D, Pollmächer T. Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka.  Fortschr Neurol Psychiat. 2001;  69 116-137
    Thieme ConnectPubMedSearch in Google Scholar
  • 58 Kametani T, Koshida H, Nagaoka T, Miyakoshi H. Hypertriglyceridemia is an independent risk factor for development of impaired fasting glucose and diabetes mellitus: a 9-year longitudinal study in Japanese.  Intern Med. 2002;  41 516-521
    PubMedSearch in Google Scholar
  • 59 McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations.  J Clin Endocrinol Metab. 2000;  85 3085-3088
    CrossrefPubMedSearch in Google Scholar
  • 60 Wetterling T. Diabetes mellitus Typ II - induziert durch atypische Neuroleptika?. Fortschr Neurol Psychiat 2003: 71 (in Druck)
    Search in Google Scholar

Prof. Dr. Tilman Wetterling

Klinik für Psychiatrie und Psychotherapie - Gerontopsychiatrie · Vivantes Klinikum Hellersdorf

Myslowitzer Str. 45

12621 Berlin

Email: t.wetterling@kh-hellersdorf.de